Michael Stocum
Chief Executive Officer
Read more

In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia).

In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU).

Michael earned dual B.S. degrees in Biochemistry and Microbiology from North Carolina State University, with a minor in Genetics and an M.S. in Biotechnology Management, while conducting two years of academic research assistantships at NCSU and the National Institutes of Health.

Michael Stocum
Chief Executive Officer

In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia).

In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU).

Michael earned dual B.S. degrees in Biochemistry and Microbiology from North Carolina State University, with a minor in Genetics and an M.S. in Biotechnology Management, while conducting two years of academic research assistantships at NCSU and the National Institutes of Health.

Nitzan Rosenfeld
Chief Scientific Officer

Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Limited, where he was head of Computational Biology and led development of molecular diagnostic tests. In 2009 Nitzan joined Cancer Research UK’s Cambridge Research Institute, now part of the University of Cambridge. His research group combines molecular technologies with genomic approaches to develop new diagnostic strategies. The focus of current research, the application of circulating tumour DNA for personalised cancer diagnostics, formed the basis of Inivata. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  At the end of 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD.

Philip Perez
Chief Commercial Officer

Philip brings to Inivata more than 20 years of industry-related experience in molecular diagnostics, clinical oncology, and precision medicine.  He has worked with companies including Becton Dickinson, Johnson & Johnson, Agendia, and Caris Life Sciences at various commercial stages including the development of a BD joint venture with QIAGEN to create PAXgene products, the commercial launch of the Veridex Circulating Tumor Cell (CTC) technology, the launch and positive coverage determination for the MammaPrint assay in the US, and the launch of the Caris Centers of Excellence for Precision Medicine network.  Throughout his career, Philip has garnered respect and increasing leadership roles to drive sales, improve client services, develop marketing, and expand managed care organizations.

Philip holds a BA in English from the University of Michigan at Ann Arbor and an MBA from the University of North Carolina at Chapel Hill.

Clive Morris
Chief Medical Officer

Clive joins Inivata from Health Innovation Manchester, an initiative to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services.  Previous to this, Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and most recently led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ.  Clive is a proven leader in the biopharmaceutical industry and has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products.  He’s accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, as well as holding an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester.  Clive is also a non-executive director of Wheatsheaf investments and the recently launched InnovateUK Medicines Discovery Catapult.

John Beeler
VP, Corporate and Business Development

John focuses on overseeing our business development related activities including partnerships with diagnostic and biopharmaceutical companies and academic institutions internationally. John has over 20 years of product and business development experience spanning the pharmaceutical and diagnostic industry including a history of having established and managed partnerships with leading pharmaceutical companies. Most recently he served as Director, Theranostics and Business Development at bioMerieux where he was responsible for executing companion diagnostic development and commercialization agreements with GlaxoSmithKline, Novartis and Gilead. John has published and presented at several scientific meetings and symposia on the topic of developing companion diagnostics and implementing personalized medicine initiatives. Dr. Beeler holds a Masters degree in biology from Villanova University and a Ph.D in pharmacology from the University of South Carolina School of Medicine.

James Clark
VP, Clinical Laboratory Operations

Dr Clark is responsible for set up and management of Inivata’s clinical testing laboratories in the US and Europe. He will also be closely involved with product development and commercialisation.

Dr Clark brings executive management level experience at the nexus of the therapeutic and diagnostic industries, specialising in Companion Diagnostics (CDx) and Next Generation Sequencing (NGS). During his career he has worked extensively in therapeutics and molecular oncology, developing and commercialising over 10 diagnostic products. James brings US-based CLIA lab experience having held executive roles in a number of oncology companies including VP Research and Development at MDx Health and COO at Response Genetics.

Dr Clark has a BSc in Microbiology and obtained his PhD from the Biochemistry Department of Glasgow University.

Tim Shannon
Chief Financial Officer

Tim joins Inivata from Baxano Surgical and Talecris Biotherapeutics, where he formulated and implemented financial controls and process improvements that supported business growth and expansion. His background in technology, life sciences, and distribution environments is particularly relevant as Inivata moves forward towards long-term business planning and commercialization of its InVision® product line. While at Talecris, Tim managed the Initial Public Offering (IPO) at a $3.28 billion valuation and has managed merger and acquisition transactions. Tim also has operational business experience across critical issues including budgeting, investor relations, systems implementation, and risk management.

Vincent Plagnol
VP, Computational Biology

Vincent was educated in Paris, France, where he obtained his bachelor of mathematics at the Ecole Normale Supérieure and an MSc in Theoretical Probability. After his PhD in Applied Mathematics and Computational Biology at the University of Southern California, he moved to the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory at the University of Cambridge in 2006 to study the genetics of autoimmune disorders, in particular type 1 diabetes. Following this postdoc in Cambridge, he became a Lecturer (2009), and then a Reader (2013), in Statistical Genetics at the University College London (UCL) Genetics Institute (UGI). At the UGI he leads a computational research group working at the intersection between statistics, computer science and genetics, with a focus on translational research, in particular rare disease genetics and non-invasive prenatal diagnostics based on cell-free fetal DNA.

He joined Inivata as the first employee and has been a driving force in developing the analytical process that optimizes the precision of the eTAm-Seq™ assay.

Jamie Platt
Head of US Commerical Laboratory Operations

Dr. Platt received her Ph.D. in Molecular & Cellular Biology from Oregon State University and completed postdoctoral training in population genetics at the University of California, Berkeley. She has extensive expertise in sequencing and molecular systematics, including population genetics. During her 15 years in clinical diagnostics, Dr. Platt has developed and validated numerous high complexity sequencing assays in the clinical areas of Oncology, Infectious Disease and Molecular Genetics and has introduced custom, industrial-grade automation to high complexity, sequencing assays. Dr. Platt has spent more than 10 years overseeing development and validation of Next Generation Sequencing Assays for both clinical diagnostics and clinical trials and has special interest in applying advanced sequencing technologies (NGS) to improve personalized healthcare.